Considering their life-long dependency on hypoglycemic therapy to prevent CV and metabolic complications due to T2DM, there is a strong need to investigate potential infectious disease risks linked to major antidiabetic drug classes, such as DPP-4 inhibitors and SGLT-2 inhibitors. This evidence concerns the gene DPP4 and infectious disease.